Previous Exacerbations Predict the Risk of Future Exacerbations After Stopping Versus Continuing Mepolizumab Treatment: Secondary Analysis of the COMET Trial

Humbert M1, Liu MC2, Moore WC3, Bel EH4, Kaneko N5, Smith SG6, Martin N7,8, Gilson MJ9, Mavropoulou E10, Price RG11, Yancey SW6, Kornmann O12

1Université Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; 2Divisions of Allergy and Clinical Immunology, Pulmonary and Critical Care Medicine, Johns Hopkins Asthma and Allergy Center, Baltimore, MD, USA; 3Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA; 4Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; 5Department of Pulmonary Medicine, Kameda Medical Center, Kamogawa, Japan; 6Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, USA; 7Global Medical Affairs, GSK, Brentford, Middlesex, UK; 8Institute for Lung Health, University of Leicester, Leicester, UK; 9Respiratory Research and Development, GSK, Uxbridge, Middlesex, UK; 10Clinical Statistics, GSK, Uxbridge, Middlesex, UK; 11Biostatistics, GSK, Stevenage, Hertfordshire, UK; 12IKF Pneumologie Frankfurt, Clinical Research Centre Respiratory Diseases, Frankfurt, Germany

Recording by Prof. Marc Humbert
This study was funded by GlaxoSmithKline (GSK ID: 201810; NCT02555371).

On behalf of all authors, an audio recording of this poster was prepared by Prof. Marc Humbert, who did not receive any payment for this recording.

The authors declare the following real or perceived conflicts of interest during the last 24 months in relation to this presentation: MH reports grants, personal fees and nonfinancial support from GSK, personal fees from AstraZeneca, Novartis, Roche, Sanofi, Teva, and Merck. MCL has received grants for clinical trials from Boehringer Ingelheim, GSK, MedImmune, Mereo BioPharm, and Gossamer Bio. WCM has received funding for clinical research and personal fees for participation in advisory boards from GSK, AstraZeneca, Genentech, and Sanofi Regeneron. EHB reports grants from AstraZeneca, GSK, Novartis, and Teva; and personal fees from AstraZeneca, GSK, Novartis, Sanofi/Regeneron, Sterna Biologicals, and Chiesi. NK reports that he has nothing to declare. SGS, NM, MJG, EM, RGP, and SWY are employees of GSK and own stocks/shares. OK has received personal fees from AstraZeneca, GSK, Novartis, Boehringer Ingelheim, Sanofi Aventis, and Roche.

Editorial support (in the form of writing assistance, including preparation of these slides under the direction and guidance of the authors, collating and incorporating authors’ comments for each draft, assembling tables and figures, grammatical editing, and referencing) was provided by Laura Murch, PhD, at Fishawack Indicia Ltd, UK, part of Fishawack Health, and was funded by GSK.
Objectives

Mepolizumab is an anti-interleukin (IL)-5 monoclonal antibody approved for use in eosinophilic diseases such as severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome.¹

The COMET study (NCT02555371) demonstrated that patients with severe eosinophilic asthma who stop long-term (≥3 years) mepolizumab treatment experience an increased rate of exacerbations and reduced asthma control compared with patients who continue mepolizumab.²

The identification of patients who are likely to exacerbate when stopping long-term mepolizumab would enable improved clinical management of a patient’s disease.

Here we present further post hoc analysis of the COMET trial, undertaken to explore whether patient baseline characteristics can predict the outcome of patients stopping versus continuing long-term mepolizumab treatment in patients with severe eosinophilic asthma.

**Methods**

**COMET (GSK ID: 201810)**

**Study design**

- **Randomized**
- **Double-blind**
- **Multicenter**

**Severe eosinophilic asthma**

- Continuous mepolizumab use for ≥3 years at randomization*
- Completed COLUMBA\(^1\) or COSMEX\(^2\) mepolizumab studies†
- Remained on controller therapy, throughout COLUMBA\(^1\) or COSMEX\(^2\)

**Patient eligibility criteria**

- **Part C: Double-blind treatment period**
  - **Part A:** 0–132 weeks (Variable)
  - **Part B:** 4–8 weeks (Fixed)

- **Screening and run-in open-label phases**
  - **Week:** −4

**Primary endpoint**

- Time to first clinically significant exacerbation

**Post hoc analyses\(^3\)**

- Exacerbations in the year prior to randomization (0, 1, ≥2)
- Use of maintenance OCS (yes/no)
- Blood eosinophil count (<50, 50–<150, ≥150 cells/µL)

**Baseline characteristics assessed to predict risk of clinically significant exacerbation**

- ACQ-5 score (<0.75, 0.75–<1.50, ≥1.50)
- Presence of nasal polyps (yes/no)
- Presence of sinusitis (yes/no)

---

1. COLUMBA (GSK ID MEA115666; NCT01691859); 2. COSMEX (GSK ID 201312; NCT02135692); 3. Rosenkranz GK. Biom J 2016; 58(5):1217–28.
Results from the overall study population

• 295 patients exposed to continuous mepolizumab treatment for ≥3 years were randomized 1:1 to stop (switch to placebo, n=151) or continue mepolizumab treatment (100 mg SC every 4 weeks, n=144) for 52 weeks.

• Hazard ratios have been expressed as placebo/mepolizumab; where a hazard ratio >1 favors mepolizumab (increased risk of exacerbation with placebo).

• Stopping versus continuing mepolizumab increased the risk of experiencing an exacerbation in the next 52 weeks by 61%.

Estimated from Cox proportional hazards model with covariates of treatment group, region, exacerbations in the year prior to randomization and baseline maintenance OCS therapy (OCS vs no OCS).

*A clinically significant exacerbation was verified using data to confirm that the exacerbation was associated with changes in peak flow, rescue medication use, nocturnal awakening due to asthma symptoms requiring rescue medication use or symptoms.

CI, confidence interval; OCS, oral corticosteroids; SC, subcutaneous

Number of prior exacerbations predictive of risk of exacerbation

- Number of exacerbations in the year prior to randomization was a strong prognostic factor for risk of exacerbation during COMET, with increasing risk of exacerbation associated with a greater number of exacerbation events in the year prior to randomization.
  - At Week 52, patients who experienced ≥2 exacerbations in the year prior to randomization had similar risk of exacerbation during COMET whether they stopped (88.6%) or continued (94.9%) mepolizumab.
  - Patients who experienced ≤1 exacerbation in the year prior had longer time to first exacerbation when continuing versus stopping mepolizumab.
  - This benefit was not seen in patients who experienced ≥2 exacerbations in the year prior to randomization.
Risk of exacerbation for patients who stop vs continue mepolizumab

- Stopping versus continuing mepolizumab increased the risk of exacerbation in the next 52 weeks (during COMET).
  - For patients with 0 exacerbations in the year prior, stopping mepolizumab increased the risk by 74%.
  - For patients with 1 exacerbation in the year prior, stopping mepolizumab increased the risk by 180%.
  - This increased risk from stopping mepolizumab was not seen for patients with ≥2 exacerbations in the year prior to randomization.

Estimated separately for each subgroup using a Cox proportional hazards model with covariates of treatment group, region and baseline maintenance OCS therapy (OCS vs no OCS).

Interaction P-values: Across all categories, P=0.174; ≥2 exacerbations vs ≤1 exacerbation, P=0.017. Results in the subgroup of ≥2 prior exacerbations were similar when assessed using bias adjusted HRs following Rosenkranz model selection.

CI, confidence interval; HR, hazard ratio; OCS, oral corticosteroids; SC, subcutaneous
Change in blood eosinophils by prior exacerbation subgroups

- The differences in blood eosinophils in those who continued mepolizumab or stopped mepolizumab (switched to placebo) was also assessed by the subgroups of exacerbations in the year prior to COMET randomization (0, 1, ≥2).
- Results appeared consistent across all prior exacerbation subgroups, with blood eosinophils in participants who stopped mepolizumab (randomized to placebo) returning to baseline pre-treatment levels from Week 12 onwards in each subgroup, whereas blood eosinophils in participants who continued mepolizumab remained unchanged.

Estimated from MMRM with covariates of baseline, region, exacerbations in the year prior to randomization, baseline maintenance OCS therapy (OCS vs no OCS), treatment and visit, plus interaction terms for visit by baseline, visit by treatment group, exacerbations in the year prior to treatment group and visit by exacerbations in the year prior to treatment group.

MMRM, Mixed Model with Repeated Measures; OCS, oral corticosteroids
Risk of exacerbation at week 52

Estimated separately for each subgroup using Cox proportional hazards models with covariates of treatment group, region, exacerbations in the year prior to randomization and baseline maintenance OCS therapy (OCS vs no OCS).

4 patients (1 placebo, 3 mepolizumab) with missing blood eosinophil counts were excluded from this analyses.

CI, confidence interval; OCS, oral corticosteroids; SC, subcutaneous

No other baseline characteristic was predictive of a differential treatment effect in exacerbation risk at Week 52
Conclusions

- Following ≥3 years of mepolizumab treatment, the number of exacerbations in the year prior to COMET randomization was a strong prognostic factor to predict future exacerbation risk.
- Patients who had ≤1 prior exacerbation were at higher risk of exacerbation when stopping versus continuing mepolizumab, consistent with the primary findings of COMET.
- Patients with ≥2 prior exacerbations had a similar exacerbation risk after stopping or continuing mepolizumab; however, this subgroup was small.
- Differences in blood eosinophil count were consistent across all subgroups of exacerbations in year prior to randomization.
  - Blood eosinophils in participants who stopped mepolizumab returned to pre-treatment levels from Week 12 onwards in each prior exacerbation subgroup whereas blood eosinophils in participants who continued mepolizumab remained unchanged.
- Other baseline characteristics analyzed included the use of maintenance OCS, blood eosinophil count, ACQ-5 score, and presence of nasal polyps or sinusitis, which did not identify a differential treatment effect in exacerbation risk at Week 52.
- These data are from post hoc analyses, so should be interpreted with caution and considered as hypothesis generating.
- Further studies are required to understand the impact of discontinuing mepolizumab in patients with a high (≥2) number of prior exacerbations.